BTW
BIO icon

Boston Trust Walden’s Bio-Rad Laboratories Class A BIO Stock Holding History

Boston Trust Walden’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.6M Buy
111,167
+17,672
+19% +$5.01M 0.25% 141
2026
Q1 		$26.1M Buy
93,495
+3,657
+4% +$1.05M 0.21% 159
2025
Q4 		$27.2M Sell
89,838
-5,610
-6% -$1.75M 0.21% 164
2025
Q3 		$26.8M Buy
+95,448
New +$26M 0.2% 166

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Boston Trust Walden's BIO Position: Q2 2026 in Review

Boston Trust Walden increased its Bio-Rad Laboratories Class A (BIO) stake by 19% in Q2 2026, buying an estimated $5.01M and bringing the position to 111,167 shares worth $32.6M. The position accounts for 0.25% of the portfolio, ranked #141.

Boston Trust Walden first reported a position in BIO in Q3 2025 and has held it in 4 quarters since. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Boston Trust Walden held 111,167 shares of Bio-Rad Laboratories Class A worth $32.6M as of Q2 2026.
  • Boston Trust Walden bought 17,672 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $5.01M.
  • Bio-Rad Laboratories Class A made up 0.25% of Boston Trust Walden's portfolio in Q2 2026, its #141 holding.
  • Boston Trust Walden first reported a position in Bio-Rad Laboratories Class A in Q3 2025 and has held it in 4 quarters since.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Boston Trust Walden's 13F filing for Q2 2026, filed 24 Jul 2026.